EUCTR2007-000535-26-IT进行中（未招募）不适用
SwiTching from etAnercept to iNfliximab in the treatment of moderate to severe psoriasis; a multi-center, open label trial evaluating the efficacy, tOlerance and safety (TANGO) - TANGO
SCHERING-PLOUGH0 个研究点目标入组 100 人开始时间: 2007年8月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The subject must meet ALL of the criteria listed below for entry: 1. Subjects must be >=18 to <=75 years of age at Screening, of either sex, and of any race. 2. Subjects must have had a diagnosis of moderate to severe psoriasis at least 6 months prior to Screening (subjects with concurrent psoriatic arthritis may be enrolled). 3. Subjects resistant or patient who must have failed 24 weeks of treatment with etanercept. (Definition of resistant patient: patient who has not modified or presents an increase in his PASI score or BSA affected after 12 weeks of etanercept treatment. Definition of patient failure: patient who has not reached PASI75 or presents BSA >=10 at Screening visit (V1) after 24 weeks of etanercept treatment. 4. Subjects who have not reached PASI 75 at Screening visit (V1) after 24 weeks of etanercept treatment or resistant ab initio to etanercept. 5. Subjects must agree to avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet light sources during the study. 6. Subjects are considered eligible according to the following tuberculosis (TB) screening criteria: a. Have no history of latent or active TB prior to screening; b. Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination; c. Have had no recent close contact with a person with active TB or, if there has been such contact, will be referred to a physician specializing in TB to undergo additional evaluation and, if warranted, receive appropriate treatment for latent TB prior to or simultaneously with the first administration of study medication; d. Within 1 month prior to the first administration of study medication, either have negative diagnostic TB test results (defined as 2 negative tuberculin skin tests) OR have a newly identified positive diagnostic TB test result (defined as at least 1 positive tuberculin skin tests) during screening in which active TB has been ruled out and for which appropriate treatment for latent TB has been initiated either prior to or simultaneously with the first administration of study medication; 8. Subjects must have had a chest x-ray (posterior-anterior and lateral) within 3 months prior to Screening with no evidence of malignancy, infection, fibrosis, or current or old active TB. 9. Subjects? Screening clinical laboratory tests (CBC, blood chemistry, and urine analysis) must be within the following parameters: a. Hemoglobin >=10 g/dL b. White blood cells >=3.5 x 109/L c. Neutrophils >=1.5 x 109/L d. Platelets >=100 x 109/L e. Serum creatinine <1.5 mg/dL f. Aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and gamma-glutamyltransferase <=1.5 x upper limit of normal g. Total bilirubin <=1.5 x upper limit of normal 9. Subjects must be free of any clinically significant disease (other than psoriasis or psoriatic arthritis) that would interfere with the study evaluations. 10. Subjects must be willing to give written informed consent and be able to adhere to dose and visit schedules. 11. Women of childbearing potential and all men must be using adequate birth control measures (eg, abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, or surgical sterilization) and must continue using such measures until 6 months after receiving the last dose of study medication. 12. Female subjects of childbearing potential must have a negative serum pregnancy test (beta-hCG) at Screening and a negative urin
排除标准
- •The subject will be excluded from entry if ANY of the criteria listed below are met: 1. Subjects who achieve PASI75 after 24 weeks of etanercept treatment. Subjects who have BSA < 10 after 24 weeks of etanercept treatment. 2. Subjects who have current drug-induced psoriasis (eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium). 3. Female subjects who are pregnant, nursing, and both men and women who are planning pregnancy during the study period or during the 6 months after receiving the last dose of study medication. 4. Subjects previously treated with infliximab. 5. Subjects who are currently taking or have taken the following drugs within the specified time frame prior to Baseline (see Section 6.2): a. any live virus or bacterial vaccinations received within 3 months. b. any systemic medications/treatments that could affect psoriasis or PASI evaluations within 4 weeks. c. any systemic immunosuppressants within 4 weeks. d. lithium within 4 weeks.Any topical medications/treatments that could affect psoriasis or PASI evaluations within 2 weeks. The only allowed topical treatments for psoriasis are shampoos (containing salicylic acid only) and topical moisturizers. Subjects should not use these topical agents during the morning prior to a study visit. Non-medicated shampoos may be used on the morning of a visit. 6. Subjects who have a concomitant diagnosis of congestive heart failure (CHF), including medically-controlled asymptomatic subjects. 7. Subjects who have a history of chronic or recurrent infectious disease, including but not limited to, chronic renal infection, chronic chest infection (eg, bronchiectasis), recurrent urinary tract infection (recurrent pyelonephritis or chronic nonremitting cystitis), or open, draining, or infected skin wounds or ulcers. 8. Subjects who have had or have a serious infection (eg, hepatitis, pneumonia or pyelonephritis), or have been hospitalized or received intravenous (IV) antibiotics for an infection during the 2 months prior to Screening. 9. Subjects who have or have had an opportunistic infection (eg, cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months prior to Screening. 10. Subjects who have or have had a Herpes zoster infection within 2 months prior to Screening. 11. Subjects who are known to be infected with human immunodeficiency virus, hepatitis B, or hepatitis C. 12. Subjects who have a history of any clinically significant AEs (including allergic reactions) to murine or chimeric proteins or human/murine recombinant products. 13. Subjects who have current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease. 14. Subjects who have a history of demyelinating disease or symptoms suggestive of multiple sclerosis or optic neuritis. 15. Subjects who have current signs and symptoms or history of systemic lupus erythematosus. 16. Subjects who have a transplanted organ (with the exception of a corneal transplant >3 months prior to Screening). 17. Subjects who have a known history of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location. 18. Subjects who have any known malignancy or have a history of
研究者
相似试验
进行中（未招募）
不适用
swiTching from etAnercept to iNfliximab in the treatment of moderate to severe psoriasis; a multi-center, open label trial evaluating the efficacy, tOlerance and safety (TANGO) - TANGOmoderate to severe psoriasis that are resistent to etanercept ab initio or have failed 24 weeks of treatment with etanerceptMedDRA version: 9.1Level: LLTClassification code 10037153Term: PsoriasisEUCTR2007-000535-26-BESchering Plough S.p.A.100
已完成
4 期
A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)PsoriasisNCT00686595Merck Sharp & Dohme LLC48
已完成
4 期
Switching from efavirenz/tenofovir/emtricitabine (TDF/FTC/EFV) to abacavir/lamivudine/maraviroc (ABC/3TC/MVC) to assess antiretroviral activity in cerebrospinal fluidHuman immunodeficiency virus (HIV)Infections and InfestationsISRCTN08592155Institute of Biomedical Investigations of Bellvitge [Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)] (Spain)15
进行中（未招募）
4 期
Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound and biomarker assessmentsRheumatoid arthritisJPRN-jRCTs071190030Kawakami Atsushi80
进行中（未招募）
4 期
Efficacy of Etanercept Biosimilar Switching from Etanercept Reference Product, using Ultrasound and Clinical Data in Outcomes of Real World Therapy (ESCORT-NGSK Study):Study protocol for an interventional, multicenter, open-label, single-arm clinical trialRheumatoid arthritisJPRN-jRCTs071190046Kawakami Atsushi62